With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | With 86 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university that pursues excellence in education, research and knowledge transfer. Driven by its motto, “To learn and to apply, for the benefit of mankind”, the University nurtures socially responsible professionals and leaders and pursues world-leading research and innovation for societal benefits. | With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. We strive in inter-disciplinary research and impactful innovations to address real-world challenges.
SPIKA TECH
Spika Tech is a company focused on applying Artificial Intelligence algorithms to tackle complex problems using deep technology. Our work is grounded in advanced knowledge of intelligent and adaptive systems, using cutting-edge techniques like generative AI, large language models, mathematical optimisation, explainable AI, and frameworks that combine automated decisions with human oversight. We have already shown our impact in fields like defence, healthcare, robotics, and the development of autonomous systems, where we’ve brought our capabilities into high-level projects, both in innovation and in internationally scoped consortia. We’ve been widely recognised for upholding the highest standards in quality, safety, and excellence in every project we undertake.
SCHOTT MINIFAB
SCHOTT MINIFAB provides integrated services for contract design, development and manufacturing of diagnostic and life science consumables – innovation to help you introduce new discoveries, enable precise health care treatments and improve patients outcomes. | SCHOTT MINIFAB provides contract design, development, and manufacturing services for companies in the diagnostics and life science industries. Our team of experts has a deep understanding of the industry-specific challenges and offers innovative solutions that drive cost-efficiencies and facilitate innovation. We specialize in streamlining the process from product development to pilot line to high-volume manufacturing of diagnostic or life science research consumables, with a focus on glass and polymer microfluidics and microarrays. | SCHOTT MINIFAB is your proven partner in contract design, development, and manufacturing for life science research and diagnostic consumables. We understand the hurdles in bringing novel innovations to full commercialization, so we have developed a process and infrastructure to meet your performance, quality, and cost requirements. Seamlessly transitioning from development to manufacturing, your product journey to improve patient care or to advance scientific discovery is closer to reality.
Saudi Commission for Health Specialties
The Saudi Commission for Health Specialties (SCFHS) was established in 1992 as a scientific professional body to regulate the work of health practitioners. It undertakes the tasks of documenting and evaluating the qualifications and experience of health practitioners, in addition to registering and classifying them to practice health professions in the Kingdom of Saudi Arabia. The SCFHS also supervises the Saudi Board Certification programs for health training in all health specialties, approves training centers, and issues Saudi Board certificates. The SCFHS also supervises the improvement of the level and efficiency of health workers by approving centers and programs for continuing education and professional development, in addition to approving the establishment of specialized scientific health associations and supervising them.
Sano Centre for Computational Medicine
Sano is a non-profit research institute dedicated to the advancement of computational medicine inspired to digitally transform healthcare by unlocking the value of data and enabling the data-driven health decisions. We use computing to find new ways to keep people healthy. Sano enjoys status of a European “Teaming for Excellence” center and is proudly based in Kraków, Poland.
Quanttrace
Quanttrace: Pioneering Non-Invasive Therapeutic Drug Monitoring Quanttrace is a spin-off from the Laboratory of Neuroengineering at the National University of San Martín (UNSAM, Buenos Aires, Argentina). We are pioneers in non-invasive therapeutic drug monitoring, developing devices that personalize healthcare without interfering with patients’ daily lives. Successful pharmacological treatment relies on patient adherence. However, even perfect adherence can’t prevent plasma level variability due to individual differences in absorption, metabolism, and sensitivity. Personalized medicine aims for optimal drug levels tailored to each individual, especially for medications with narrow therapeutic ranges (such as oncologic drugs, antipsychotics, anticonvulsants, and antibiotics). Our challenge at Quanttrace is to provide the pharmaceutical and biotech industries with in-situ methods for measuring plasma concentrations without disrupting daily routines. Our technology is wearable, non-invasive, and works in everyday environments without laboratory equipment. Data is processed on a mobile device, and results are immediate. Quanttrace merges complex signal analysis and AI tools with advanced medicinal chemistry, allowing patients and caregivers to monitor plasma drug concentration at home and communicate directly with their doctors. This represents a significant advancement towards precision medicine and in-situ dose control, ensuring optimal treatment adherence. At Quanttrace we are currently conducting preclinical trials in small and large animals to validate our technology. At this stage, we have filed a provisional patent to protect our innovation. Right now we are actively seeking investment to refine our development and successfully conclude our preclinical trials and go into a clinical phase of research. We are open to hearing from investors who wish to partner with us in this innovative and exciting research pipeline. keywords: personalized medicine, precision medicine, precision healthcare, patient monitoring device, in-situ dose control, therapeutic drug monitoring, artificial intelligence, AI, medicinal chemistry, at home monitoring.
PulManage, Inc.
PulManage, Inc is a software company specializing in remote monitoring of chronic lung disease such as COPD. The proprietary platform utilizes a mobile application to collect spirometry data from a handheld medical device and push that information directly into a secure, web-based application for patients to document symptoms and respiratory function. Simultaneously, providers can survey and trend the patient’s condition remotely. The platform can be utilized to create value and document physiologic and therapeutic response longitudinally. | PulManage, Inc., a digital health company, has developed a platform for chronic lung disease that pairs with FDA-approved lung-function devices. The platform provides critical lung-function data coupled with symptom management and respiratory biomarkers for patients and medical teams in a secure portal. The system allows medical providers and clinical researchers to survey respiratory status remotely. The company is developing predictive algorithms using AI to better understand disease patterns and mitigate risk. More than 24 million people in the United States live with chronic lung diseases such as COPD or asthma. When combined with lung cancer and respiratory diseases like COVID-19 or influenza, lung disease is the number one cause of death by disease in America. | PulManage, Inc. is transforming respiratory clinical trials in rare diseases by solving persistent challenges like data variability, patient recruitment, and operational inefficiencies. Traditional in-person spirometry is burdensome and technician-dependent, leading to low data fidelity. PulManage’s compliant, scalable platform provides real-time, high-quality remote spirometry guided by credentialed respiratory therapists, reducing variability by up to 40% and ensuring global ATS/ERS compliance. Frequent, standardized assessments and real-time analytics enhance data fidelity and disease characterization. Shared dashboards improve sponsor oversight. Proven in rural COPD studies, the platform boosts enrollment, communication, and data quality. It’s used by academic centers and a rare disease community for trials and real-world evidence, with future support for multilingual trials, wearables, and forecasting analytics.
pRxEngage
Have you ever felt like finding the right clinical trial is as complex as online dating, but without the fun swiping? At pRxEngage, we are revolutionising how patients and pioneering research connect, making the process as intuitive and empowering as finding your perfect match! The current scene in clinical trials is often slow, incredibly expensive, and frankly, fails both sponsors and the very patients it aims to help. While over 80% of patients are eager to join trials, a mere 30% actually do. This massive disconnect means trials are frequently delayed, racking up costs of £420,000 to over £6 million per day, and vital new drugs are stuck in development. We are here to change that. pRxEngage goes beyond simply recruiting; we’re about deep, sustained engagement. We look past just medical suitability to address whether a trial truly fits into a person’s life, helping them overcome any doubts. By making patients active ‘consumers’ of the trial, opting in at each stage, we build an ever-deepening relationship. The outcome? Better retention, greater adherence, and faster trial success. Our platform makes finding a trial as simple as swiping right or left. Our AI-powered system guides patients with easy-to-understand, jargon-free information and tools based on behavioural science, like Self-Determination Theory, to help them assess their suitability. Then, it seamlessly connects them directly to trial sites. For sponsors and sites, we provide real-time data dashboards and predictive analytics to identify suitable participants and improve retention. Our AI even helps streamline trial setup by parsing documents and generating clear summaries for participants. pRxEngage is engineered to redefine the connection between high-potential patients and appropriate clinical trials, accelerating crucial enrolment timelines. We foster sustained participant engagement, moving beyond conventional recruitment metrics to cultivate a more committed and informed cohort from the outset. This results in a higher-calibre, more dedicated participant pool from the initial stages, directly contributing to improved trial success rates, enhanced participant retention, and greater adherence to study protocols. We are truly unique because we combine community partnerships, predictive engagement, and operational support. We work with patients, sites, sponsors, charities, and patient organisations, building trust and integrating feedback. Our predictive tools identify engaged participants, and our operational support offers workflow and triage tools for sites and sponsors to boost efficiency. We are an additive solution, meaning we work alongside existing sponsor tools, making adoption easy. We are proud to be developing groups of community partners and ambassadors. This includes fantastic organisations like PiCC Unite, The PBC Foundation, and Don’tBePatient, with several more in advanced development. These collaborations are crucial to our mission of broadening awareness and access to research opportunities, ensuring that value and information remain within these communities. Our success springs from our visionary leadership and proven execution. Our Founder and CEO, Keith Berelowitz, brings over two decades of experience, having brought 12 drugs to market and achieved top-enrolling site status in numerous multi-centre trials. Charlie Myrick, our CTO, is a founding CTO with a background in architecting global engineering solutions and building HIPAA-certified SaaS patient tracking systems. Ethan Graff-Radford, our Head of Product, has experience in product management at an A16Z-backed company and has implemented agile methodologies for health-tech solutions. Our board members, David Guthrie and Daniel Graff-Radford, bring decades of experience shaping health-tech, scaling companies, and providing strategic technological oversight. This combined expertise means pRxEngage represents the convergence of profound clinical trial operational knowledge with sophisticated technological execution. Our intellectual property strategy focuses on our registered trademark for the pRxEngage brand, which is crucial for establishing our identity as we turn clinical trial interest into action. Beyond branding, we rely significantly on trade secrets to protect our unique algorithms, data analytics methodologies, behavioural science integration, and operational workflows. These elements fundamentally change the focus from mere recruiting to long-term patient engagement, retention, and measurable return on investment. Want to learn more about how pRxEngage is changing the game for clinical trials? Check out our company one-pager (https://docsend.com/v/y95hx/swiperightonresearch) and read our recent blog (https://docsend.com/v/y95hx/makingpatientfirstmeansomethingbeyondconsent) post to see our thinking in action. #pRxEngaged #GetpRxEngaged #ClinicalTrials #PatientEngagement #HealthcareInnovation #MedTech #ClinicalResearch
ProMedix
ProMedix Inc is a medical device spinout company from Oregon Health & Sciences University. Our fingertip, circulatory dysfunction monitoring device, “PeriFRL” saves thousands of lives by enabling physicians (through tracking minute changes in Capillary Refill Time – “CRT”) to rapidly identify septic shock, and noninvasively monitor efficacy of therapeutic interventions once sepsis is diagnosed – all in real-time, and all at the patient bedside. The ProMedix PeriFRL commercialization glidepath includes connectivity and use of multivariable predictive algorithms. Current sepsis forecasting platforms lack physiologic input beyond simple vital signs and suffer from a high false-positive rate. Adding objective CRT measurement, a high-value patient-specific physiologic marker, to sepsis prediction algorithms will reduce the rate of false positive tests, making the risk prediction models more actionable than what is currently available. Including this patient-specific measurement can also address some of the pitfalls commonly associated with AI risk prediction model implementation. This set of customers is broad – from EHR companies (e.g., POC Advisor), to partnered data integration platforms (e.g., Validic). No one else has a serial-capable, stand-alone ability to monitor sepsis. There are several pathways into the marketplace. Optical detection of peripheral microcirculation facilitates early recognition of onset of sepsis; meeting calls from end-users for increased responsiveness and improve value-based care. Therefore, hospitals will be our initial focus for direct sales of our noninvasive PeriFRL monitor – with a primary emphasis on emergency room, intensive care, and med surg departments. Once ensconced, we will rapidly scale to partnering with either forecasting platform providers (as described above), or with targeted strategics (like Baxter and Medtronic; both of whom we are presently under NDA) to integrate our outputs into their existing patient monitoring telemetry portfolio (either via patient vitals, or in improved perfusion monitoring).
Nia Health GmbH
Nia Health is a digital health technology company specializing in advanced medical research solutions, emerging from the interdisciplinary research ecosystem of Charité – Universitätsmedizin Berlin, a globally recognized center for medical innovation. Our portfolio includes CE-certified medical device applications for chronic inflammatory skin conditions, specifically developed for patients with atopic dermatitis and psoriasis. These medical-grade digital monitoring platforms provide certified medical documentation and patient management tools, setting new standards in digital therapeutics. Our proprietary platform combines machine vision AI and advanced machine learning to revolutionize medical research and patient monitoring. By delivering objective, quantifiable assessments across multiple medical domains, we enable precise dermatological, immunological, and pharmaceutical research insights. Key technological innovations include: – AI-powered severity classification – Real-time disease progression tracking – Smartphone and web-based monitoring tools – Predictive treatment response analytics The platform offers comprehensive solutions for pharmaceutical companies, enabling: – Precise clinical trial patient screening – Objective treatment effectiveness measurement – Automated data collection – Privacy-compliant patient monitoring Our machine vision technology can assess conditions across dermatology, wound management, oncology, and infectious disease tracking, providing unprecedented insights into disease progression and treatment responses. By seamlessly integrating advanced imaging technologies with sophisticated data analytics, Nia Health delivers scalable digital solutions that enhance medical decision-making, optimize research processes, and drive innovation in healthcare technology. Driven by an interdisciplinary approach combining medical expertise and cutting-edge technological innovation, we are committed to transforming medical research through intelligent, data-driven solutions.